Clinical Trials Directory

Trials / Unknown

UnknownNCT00410462

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
118 (actual)
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC · Network
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Drugs used in chemotherapy, such as brostallicin and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This randomized phase II trial is studying the side effects and how well brostallicin or doxorubicin works as first-line therapy in treating patients with relapsed, refractory, or metastatic soft tissue sarcoma.

Detailed description

OBJECTIVES: Primary * Determine the activity and safety of brostallicin vs doxorubicin hydrochloride as first-line therapy in patients with relapsed, refractory, or metastatic soft tissue sarcoma. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating and age(younger than 60 years vs 60 years and over). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive brostallicin IV over 10 minutes on day 1. * Arm II: Patients receive doxorubicin hydrochloride IV over 10 minutes on day 1. In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter. PROJECTED ACCRUAL: A total of 108 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
DRUGbrostallicin
DRUGdoxorubicin hydrochloride

Timeline

Start date
2006-10-01
Primary completion
2008-09-01
First posted
2006-12-13
Last updated
2014-08-08

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT00410462. Inclusion in this directory is not an endorsement.